Johnson & Johnson vs. Summit Therapeutics Inc. Common Stock
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| JNJ | SMMT | |
|---|---|---|
| Market Cap | $670.99 billion | $13.67 billion |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-856,089,000 |
JNJ leads on 2 of 2 size & scale factors.
Valuation
| JNJ | SMMT | |
|---|---|---|
| P/E Ratio | 31.94 | — |
| Price / Book | 7.90 | 21.69 |
| Price / Sales | 6.85 | — |
JNJ leads on 1 of 1 valuation factors.
Profitability
| JNJ | SMMT | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | -135.89% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| JNJ | SMMT | |
|---|---|---|
| Dividend Yield | 1.95% | — |
| Payout Ratio | 62.18 | — |
JNJ and SMMT split the dividend factors evenly.
Risk & Sentiment
| JNJ | SMMT | |
|---|---|---|
| Short Interest | 0.67% | 0.00% |
SMMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, SMMT overview, SMMT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.